<html>
<head>PUBMED IDs for CXCL17</head>
<body bgcolor='#C5F0F2'><h1>CXCL17</h1><a href='https://pubmed.ncbi.nlm.nih.gov/20955708/'>CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis.</a> January 21  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/22952881/'>CXCL17 expression by tumor cells recruits CD11b+Gr1 high F4/80- cells and promotes tumor progression.</a> February 8  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/25303284/'>CXCL17 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma.</a> December 19  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/27180200/'>Amendment of the cytokine profile in macrophages subsequent to their interaction with smooth muscle cells: Differential modulation by fractalkine and resistin.</a> May 18  2016<br></body></html>
